Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)

NCT00216216 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT00216216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2005
Completion date
October 31, 2005
Enrollment
43 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer